VERU News and Press, Veru Inc. From 09/06/22

MIAMI, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will present a...

In today's bearish market, consistent growth is hard to come by, but it still exists. Even with inflation and threats of recession, a few companies have so many positive milestones coming up that their share prices keep rising even as the market falls or moves sideways. For investors lo...

Veru (NASDAQ: VERU) , a high-flying cancer and COVID-19 stock, is in full-on retreat mode today. Specifically, the biotech's shares were down by a hefty 17%, on average volume, as of 12:38 p.m. ET Tuesday afternoon. What's causing investors to head for the exits today? The good ...

The Australian Therapeutic Goods Administration (TGA) had determined that Veru's ( NASDAQ: VERU ) sabizabulin treatment in hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome qualifies for an expedited, provisional registration regulato...

MIAMI, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that Australia’s Therapeu...

MIAMI, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Jason Davies ...

Gainers: Cedar Realty Trust ( CDR ) +207% . Neptune Wellness Solutions ( NEPT ) +122% . Edible Garden AG Incorporated ( EDBL ) +57% . Indonesia Energy Corporation ( INDO ) +37% . Hillstream BioPharma ( HILS ) +30% . Mind Medi...

COVID-19 drugmaker Veru ( NASDAQ: VERU ) snapped a six-day rally Thursday, losing ~13% in the morning hours after one of the company's directors sold over $2.0M worth of VERU stock as part of an option exercise. According to an SEC filing submitted on Wednesday, VERU d...

Pharmaceutical companies can grab the attention of investors through positive clinical studies and expectations of a potential U.S. Food and Drug Administration (FDA) approval. On the other hand, investors don't typically care for a quarterly earnings miss. So what happens to a company'...

Shares of Veru (NASDAQ: VERU) were flying 31.6% higher at 12:14 p.m. ET on Thursday. The big gain came after the drugmaker provided its fiscal 2022 third-quarter update before the market opened. Veru's Q3 results didn't appear to justify the sizable jump for the stock. The compa...